Merck’s V114 pneumococcal vaccine candidate succeeds in two phase 3 trials

This article was originally published here

Both the late-stage trials – PNEU-WAY and PNEU-FLU evaluated the safety, tolerability, and immunogenicity of V114, said Merck. The investigational vaccine is being developed for the prevention of

The post Merck’s V114 pneumococcal vaccine candidate succeeds in two phase 3 trials appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply